The effectiveness of cancer treatment could be predicted by a gene fault.

According to research presented at the American Society for Clinical Oncology, women with faults in a gene known as p53 are 50 per cent less likely to survive following treatment with carboplatin alone.

However, if they are also treated with paclitaxel they tended to be more likely to show survival benefit compared to the standard.

Meanwhile, those without such gene mutations had better survival rates but did not benefit from having paclitaxel added to their treatment, meaning that they can be spared unnecessary side effects.

Professor Hilary Calvert, who led the study, commented: "These results show that ovarian cancer patients whose tumour had a faulty p53 gene survive longer if given paclitaxel in addition to carboplatin.

"Although survival rates have improved dramatically in recent years, ovarian cancer remains a deadly cancer in women and efforts to improve survival by targeting treatments at those most likely to benefit are urgently needed."  

Comment on this page »


Latest news

AXA PPP healthcare win at UK Customer Experience awards 2015

David Mobbs retires as CEO of Nuffield Health

King's victorious at World Transplant Games

Could gene fault predict cancer treatment success?
Connect with us on:

This site compiles with the HONcode standard for trustworthy health information